The overall objective will be to evaluate clinical predictors of outcomes in patients who undergo endovenous sclerotherapy for the treatment of varicose veins.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Frequency of obliteratin (total or partial) of injected varicosity.
Timeframe: assessment will be at 1, 12, and 26 weeks.
Improvement in venous stasis symptoms.
Timeframe: assessment will be at 1, 12, and 26 weeks
Change in quality of life.
Timeframe: assessment will be at 1, 12, and 26 weeks
Associations between clinical outcomes and biomarkers.
Timeframe: assessment will be at 1, 12, and 26 weeks